Xenetic Biosciences, Inc. (NASDAQ:XBIO)

PRESS RELEASE

published on 07/30/2025 at 15:00, 1 year 1 month ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences collaborates with PeriNess for an exploratory clinical study of DNase I with anti-CD19 CAR T cells in large B cell lymphoma patients at Tel Aviv Sourasky Medical Center

Xenetic Biosciences DNase I PeriNess Large B Cell Lymphoma Anti-CD19 CAR T Cells
BRIEF

published on 07/23/2025 at 14:35, 1 year 1 month ago

Xenetic Biosciences étend sa collaboration avec Scripps Research

Biosciences Xénétiques Thérapie Par Cellules CAR-T Développement Préclinique Plateforme DNase-I Collaboration En Oncologie
BRIEF

published on 07/23/2025 at 14:35, 1 year 1 month ago

Xenetic Biosciences Expands Collaboration with Scripps Research

Xenetic Biosciences CAR T-cell Therapy Preclinical Development DNase-I Platform Oncology Collaboration
PRESS RELEASE

published on 07/23/2025 at 14:30, 1 year 1 month ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 1 year 2 months ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 1 year 2 months ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 1 year 2 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 1 year 4 months ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 1 year 4 months ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 1 year 4 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I

Published on 09/17/2026 at 15:55, 1 hour 43 minutes ago

Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 2 hours 13 minutes ago

AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 2 hours 38 minutes ago

Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 2 hours 38 minutes ago

ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 2 hours 48 minutes ago

Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner

View all ACCESSWIRE

Published on 09/17/2026 at 17:15, 23 minutes ago

Huawei Unveils the Industry's First NPO Optical Engine with Built-in Light Source, Hi-ONE, Leading the Way in High-Speed Optical Interconnect Technology Innovation
Published on 09/17/2026 at 17:00, 38 minutes ago

Advancing the Agentic World, Building a Solid Silicon Foundation
Published on 09/17/2026 at 16:48, 49 minutes ago

Elmos Semiconductor SE secures additional wafer capacity in Dortmund
Published on 09/17/2026 at 15:30, 2 hours 8 minutes ago

Huawei Introduces OceanStor M900 Context Memory Storage to Accelerate AI Inference in Hyperscale Data Centers
Published on 09/17/2026 at 15:08, 2 hours 30 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

View all EQS

Published on 09/16/2026 at 20:46, 20 hours 52 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 18:45, 22 hours 53 minutes ago

STEF : Droits de vote au 31 08 2026
Published on 09/16/2026 at 18:06, 23 hours 31 minutes ago

LNA SANTE : Résultats semestriels 2026
Published on 09/16/2026 at 17:45, 23 hours 53 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 23 hours 53 minutes ago

5e édition de l’émission “On the way up”

View all LES ECHOS COMFI WIRE

News